SB269970 HCl

C57BL6/J mice

SB-269970 HCl is a hydrochloride salt form of SB-269970, which is a 5-HT7 receptor antagonist with pKi of 8.3.

SB-269970 HCl is a hydrochloride salt form of SB-269970 which is a potent 5-HT 7 receptor antagonist.

8.3 (pKi) [1], 8.3 (pKi) [1], 8.3 (pKi) [1], 8.3 (pKi) [1], 8.3 (pKi) [1], 8.3 (pKi) [1]

SB-269970 (10 mg/kg and 30 mg/kg) significantly reduces the effects of amphetamine by 25 and 27%, respectively, and blocks the effects of ketamine by 38% (10 mg/kg) and 30% (30 mg/kg). SB-269970 significantly reduces amphetamine-induced hyperactivity in wild-type mice and is without effects in 5-HT7 knockout mice. Systemic administration of SB-269970 (30 mg/kg) significantly reverses amphetamine disruption of PPI and did not enhance PPI by itself compared to control. [3] SB-269970 significantly reverses the deficits induced by MK-801, but not by scopolamine. SB-269970 normalizes MK-801-induced glutamate but not dopamine release in the cortex. [4] SB-269970 (in one medium dose of 0.5 or 1 mg/kg) exerts a specific antianxiety-like effect in the Vogel drinking test in rats, in the elevated plus-maze test in rats and in the four-plate test in mice. Moreover, SB-269970 (in one medium dose of 5 or 10 mg/kg) reveals antidepressant-like activity in the forced swimming and the tail suspension tests in mice. [5] SB-269970 at doses of 0.3, 1 and 3 ug exhibits an anticonflict effect which is weaker than that of diazepam (40 ug), whereas SB-269970 at doses of 3 and 10 ug had marked anti-immobility action comparable to that of imipramine (0.1 ug). [6]

SB-269970 HCl Chemical Structure

2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO